鈴木 憲史 先生のプロフィール

鈴木 憲史 先生

すずき けんし

鈴木 憲史 先生

日本赤十字社医療センター 骨髄腫アミロイドーシスセンターセンター長・薬剤部長・輸血部長

専門分野

血液腫瘍(白血病、リンパ腫、骨髄腫)、貧血、出血傾向の治療、造血幹細胞移植

紹介

日本赤十字社医療センター骨髄腫アミロイドーシスセンターにてセンター長を務める。難治性の高いアミロイドーシスの患者さんであってもトリアージをせず、「全ての患者さんに治療を試みる」ことをモットーとしており、患者さんとご家族から厚い信頼を得ている。ALアミロイドーシス患者の会の顧問医師を務めるなど、病気に対する不安を取り除くための活動にも尽力している。

略歴

1976年 国立新潟大学医学部卒業
1976年 日本赤十字社医療センター内科研修医
1978年 日本赤十字社医療センター内科医師
1982年 国立東京医科歯科大学医学部大学院専攻科 終了
1984年 国立東京大学医学部第3内科(血液学専攻)研究生 終了
1990年 日本赤十字社医療センター第2内科副部長
1995年 日本赤十字社医療センター第2内科(血液)部長
2012年 日本赤十字社医療センター副院長 (平成28年定年)
2014年 日本赤十字社医療センター薬剤部長兼務
2016年 日本赤十字社医療センター骨髄腫アミロイドーシスセンターセンター長・薬剤部長・輸血部長

所属学会・資格・役職など

日本内科学会指導医
日本血液学会指導医
功労会員
財務委員
米国血液学会会員
日本骨髄腫学会功労会員
日本免疫治療学研究会理事
レブメイト第3者評価委員会委員長
ベルケイド適正使用ガイド監修委員
厚労科研主任研究員
昭和大学客員教授

受賞・著書・論文など

1) Y.Eishi, K.Suzuki, S.Hatakeyama . Freeze-Preservation of staining solutions in enzyme histochemistry. Bull Tokyo Med and Dent Univ 29;47-52, 1982.
2) K.Suzuki, K.Hirokawa, S.Hatakeyama. Age-related change of distribution of immunoglobulin containing cells in human bone marrow –Changes in patients with benign monoclonal gammopathy and multiple myeloma Virchows Arch(Pathol Anat)404;243-251,1984. 【学位主論文】
3) K.Suzuki, T.Takemura, R.Okeda, S.Hatakeyama. Vascular changes of Methotrexate-related disseminated necrotizingLeukoencephalogy  Acta Neuropathol (Berl)65;145-149, 1984.【学位副論文】

6) K.Su

1) Y.Eishi, K.Suzuki, S.Hatakeyama . Freeze-Preservation of staining solutions in enzyme histochemistry. Bull Tokyo Med and Dent Univ 29;47-52, 1982.
2) K.Suzuki, K.Hirokawa, S.Hatakeyama. Age-related change of distribution of immunoglobulin containing cells in human bone marrow –Changes in patients with benign monoclonal gammopathy and multiple myeloma Virchows Arch(Pathol Anat)404;243-251,1984. 【学位主論文】
3) K.Suzuki, T.Takemura, R.Okeda, S.Hatakeyama. Vascular changes of Methotrexate-related disseminated necrotizingLeukoencephalogy  Acta Neuropathol (Berl)65;145-149, 1984.【学位副論文】

6) K.Suzuki, K.Hirokawa, R.Kamiyama, S.Hatakeyama. Distribution of immunoglobulin containing cells in human bone marrow of patients with leukemia. Acta Pathol Jpn 37; 193-199, 1987.
7) K.Suzuki, K.Hirokawa, T.Takemura, Y.Esaki. Age-related change in the number of mast cells in human bone marrow and spleen. Acta Haematol Jpn 51;739-745, 1988.
53)K Suzuki: Diagnosis and treatment of multiple myeloma and AL amyloidosis with focus on improvement of renal lesion. Clin Exp Nephrol. 16:659-671, 2012
54) K Suzuki: Current therapeutic strategy for Multiple myeloma. Jpn J Clin Oncol 43:116-124, 2013
55) K Suzuki: Diagnosis and Treatment of Multiple Myeloma and AL Amyloidosis with Focus on Improvement of Renal Lesion 6thAnnual World Cancer Congress-2013 Xian ,China 23/May/2013
56) Ogawa Y, Suzuki K, Hotta T et al: Phase 1/2 study of bortezomib  -melphalan- Prednisolone for previously untreated Japanese patients with multiple myeloma. Cancer Science, doi:10.1111/cas.12172,2013
57)Nakagawa Y, K Suzuki., Masaoka T et al: Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neiutropenia. J Infect Chemother 19:103-111,2013.
2014
58)Ozaki S, Harada T, Saitou T, Suzuki K et al: Survival of multiple myeloma patients aged 65-70 years in the Era of novel agents aqnd autologous stem cell transplantation. Acta Hematol. 132:211-219,2014
59) Kim K, Lee H, Kim JS, Suzuki K, et al: Clinical profiles of multiple myeloma in Asia-An Asian myeloma network study. Am J Hematol 89:751-756, 2014
60) Miyazaki K, Suzuki K: Unusual intracytoplasmic crystalline inclusions in chronic myelomonocytic leukemia with double minute chromosomes and MYC amplification: A rare case. Acta Hematol 132:68-72,2014
61) Handa H, Suzuki K, Chou T, et al. Phase 1 Study of the Investigational Proteasome Inhibitor Ixazomib Alone or in Combination with Lenalidomide–Dexamethasone (Rd) in Japanese Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2014; 124, 5752
2015
62) K Suzuki, M Ogura, Y Abe, A phase 1 study of siltuximab, an anti-IL-6 mAb, in relapsed/ refractory multiple myeloma. Int J Hematol 2015 Mar;101(3):286-94 
63) Miyazaki K, Suzuki K: Clinical and laboratory significance of CD56 (a neural cell adhesion molecule) positivity in multiple myeloma and AL amyloidosis Int J Myel 5(3): 30–35, 2015
64) Miyazaki K, S Kawai, K Suzuki: Abdominal subcutaneous fat pad aspiration and bone marrow examination for the diagnosis of AL amyloidosis: the reliability of immunohistochemistry. Int J Hematol 102:289-295,2015
65) Meshitsuka S, K Suzuki,: The efficacy and safety of a 1.6 mg/㎡ increase in a bortezomib regimens. Open J Blood Diseases 2015
J Inoue, M Ikeda, K Suzuki, et.al: The clinical significance of decrease in CD138 positive cell ratio in multiple myeloma. Rinshou ketueki 56:2311-2317,2015
66) Watanabe T, Suzuki K, Kizaki M. et al: Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.
PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. eCollection 2015.
67) Ozaki S, Suzuki K, Shimizu K. et al: Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015 Sep 18;5:e349. doi: 10.1038/bcj.2015.79.
2016
68)Watanabe T, K Suzuki, Iida S:A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma. Br J Haematol. 2016 Mar;172(5):745-56.
69) Suzuki K, Shinagawa A, Chou T. et al: Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: A phase II study. Cancer Sci. 2016 May;107(5):653-8.
70)Miyazaki K, K Suzuki: Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis. Amyloid 2016 DOI:10.1080/13506129
71) Suzuki K, et al Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study. Cancer Sci. 2016, doi: 10.1111/cas,12916.
72) Shimazaki C, Fuchida S, Suzuki K, Ishida T, Imai H, Sawamura M, Takamatsu H, Abe M, Miyamoto T, Hata H, Yamada M, Ando Y.: Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis. Int J Hematol. 2016 Jan;103(1):79-85.
73)Tsukada N, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Yoshiki Y, Abe Y, Suzuki K.
: High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases. Int J Hematol. 2016
Mar;103(3):299-305.
74) Mu S, Kuroda Y, Suzuki K et al: Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma.
Eur J Clin Pharmacol. 2016 Feb;72(2):153-61.
75) Ichinohe T, Kuroda Y, Suzuki K. et al. A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial. Exp Hematol Oncol 2016.5:11 Doi 10.1186.
76) Suzuki K, Masaki Ri, T Chou, et al: Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma: A multicentre, open-label, phase 1 study in Japan (2016)
77) Ikeda M, Tukada N, Suzuki K et al: Successful second allogeneic stem cell transplantation from a sibling donor for relapse of myelodysplastic syndrome in a recipient of a remnal transplant from his mother ; case report. Transplantation Proceedings 2016:48,3085-3087.
78)Kitamura K, Nishiyaka T, Suzuki K et al:Clinical usefulness of WT 1 mRNA expression in bone marrow detected by a new WT 1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT 1 mRNA in peripheral blood. Int J Hematol 2016,103:53-62.
79) Dimopoulos MA, Suzuki K. Moreau P et al: An Open-label, Randomised, Phase 3 Study of saftytumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): POLLUX NEJM: N Engl J Med. 2016 Oct 6;375(14):1319-1331.
80) Suzuki K, Hiroshi Handa, Takaaki Chou, et al: A Phase 1 Study of Ixazomib Alone or Combined with Lenalidomide- Dexamethasone in Japanese Patients with Relapsed/Refractory Multiple Myeloma (2016)
2017
81)Iki S, Ohgi K, Suzuki K; Eculizumab treatment improved renal hemosiderosis in a patient with paroxysmal nocturnal hemoglobinuria. Int J Hematol 2017 105:231-232
82) Miyazaki K, Suzuki K.: Capillary electrophoresis/immunosubtraction as a better alternative to immunofixation for detecting and immunotyping serum monoclonal proteins in patients with immunoglobulin light chain (AL) amyloidosis.  Amyloid. 2016 Sep 28:1-4.
83) Meshitsuka S, Shingaki S, Suzuki K, et al; Phase 2 trial of daily, oral epigallocatechin gallate in patients with light‑chain amyloidosis Int J Hematol DOI 10.1007/s12185-016-2112-1, 2016
84) Suzuki K, Sunami K, Taniwaki M.et al: Randomized phase 3 study of elotuzumab for relapsed or refractory multiple myeloma: ELOQUENT-2 Japanese patient subanalysis.
Blood Cancer J. 2017 Mar 10;7(3): e540. doi: 10.1038/bcj.2017.18. No abstract available.
85) Suzuki K, Ri M, Iida S. et al: Carfilzomib, lenalidomide and dexamethasone in patients with heavily pretreated multiple myeloma: A phase 1 study in Japan. Cancer Sci. 2017 Mar;108(3):461-468.
86) Suzuki K, Handa H, Kase Y. et al: Phase 1 study of ixazomib alone or combined with lenalidomide-dexamethasone in Japanese patients with relapsed/refractory multiple myeloma.
Int J Hematol. 2017 Apr;105(4):445-452.
87)Shingaki S, Tukada N, Suzuki K et al; Feasibility of myeloablative allogenic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma. Hematological Oncology 2017, 1-3: July
88) Futami M, Sato K, Miyazaki K, Suzuki K, Nakamura T, Tojo A.et al: Efficacy and Safety of Doubly-Regulated Vaccinia Virus in a Mouse Xenograft Model of Multiple Myeloma.
Mol Ther Oncolytics. 2017 Jul 22;6:57-68.
89) Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J; ALCYONE Trial Investigators.et al: Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. N Engl J Med. 2017 Dec 12.
2018
90)Miyazaki K, Suzuki K.; Elevation of Plasmin-α2-plasmin Inhibitor Complexes in Patients with AL Amyloidosis. Intern Med. 2018 Mar 15;57(6):775-776. doi: 10.2169/internalmedicine.9511-17. Epub 2018 Jan 11. No abstract available.
91) Kawamura K, Tsukada N, Kanda Y, Ikeda T, Yoshida A, Ueda Y, Ishida T, Suzuki K, Murakami H. The Role of Allogeneic Transplantation for Multiple Myeloma in the Era of Novel Agents: A Study from the Japanese Society of Myeloma. Biol Blood Marrow Transplant. 2018 Mar 16. pii: S1083-8791(18)30125-3. doi: 10.1016/j.bbmt.2018.03.012. [Epub ahead of print]
92) Ri M, Suzuki K, Iida S, Hatake K, Chou T, Taniwaki M, Watanabe N, Tsukamoto T. A Phase I/II Study for Dose-finding, and to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of NK012, an SN-38-Incorporating Macromolecular Polymeric Micelle, in Patients with Multiple Myeloma. Intern Med. 2018 Apr 1;57(7):939-946. doi: 10.2169/internalmedicine.9567-17. Epub 2017 Dec 8.
93) Iida S, Ichinohe T, Shinagawa A, Suzuki K, Takezako N, Aoki M. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma. Int J Hematol. 2018 Apr;107(4):460-467. doi: 10.1007/s12185-017-2390-2. Epub 2017 Dec 19.
94)Iyoda T , Yamasaki S , Hidaka, M , Kawano F , Abe Y , Suzuki, K , et al. Amelioration of NK cell function driven by Vα24+ invariant NKT cell activation in multiple myeloma. Clinical Immunology 2018 Feb, 187:76-84
95) Tan D , Lee J H , Chen W , Shimizu K , Hou J , Suzuki K , et al. Recent advances in the management of multiple myeloma: clinical impact based on resource-stratification. Consensus statement of the Asian Myeloma Network at the 16th international myeloma workshop
Leukemia and Lymphoma 2018 Feb 2, 1-13
96)Miyazaki K, Suzuki K. Abnormal Heavy/Light Chain Ratio and Matched Pair Suppression Increase Residual Disease Detection Sensitivity in Patients with Multiple Myeloma With Deep Responses. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):293-296.
doi: 10.1016/j.clml.2018.01.008. Epub 2018 Feb 19.
97) Suzuki K, Dimopoulos MA, Takezako N, Okamoto S, Shinagawa A, Matsumoto M, Kosugi H, Yoon SS, Huang SY, Qin X, Qi M, Iida S. Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer J. 2018 May 1;8(4):41. doi: 10.1038/s41408-018-0071-x.

続きを見る

鈴木 憲史先生 の所属する医療機関

日本赤十字社医療センター

TEL: 03-3400-1311

日本赤十字社医療センター

東京都渋谷区広尾4丁目1-22

東京メトロ日比谷線「広尾」駅 徒歩15分

JR山手線「恵比寿」駅 西口 都営バス 学06系統 日赤医療センター行 終点下車すぐ バス10分

- - -

診療時間: 8:30~15:00 原則紹介制 一部診療科予約制 AM受付は11:00まで、以降はPM診察となる 診療時間は原則として、AM9:00~12:00 PM13:00~終了まで 科により異なる 創立記念日(5/1)休診 臨時休診あり

診療科目: 内科 アレルギー科 血液内科 リウマチ科 外科 精神科 神経内科 脳神経外科 呼吸器外科 消化器外科 腎臓内科 心臓血管外科 小児科 小児外科 整形外科 皮膚科 泌尿器科 産婦人科 眼科 耳鼻咽喉科 リハビリテーション科 放射線科 歯科口腔外科 麻酔科 乳腺外科

鈴木 憲史 先生 の記事